Piramal Pharma (NSE:PPLPHARMA) Debt-to-Equity : N/A (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Debt-to-Equity?

Piramal Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Piramal Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Piramal Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2024 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Piramal Pharma's Debt-to-Equity or its related term are showing as below:

NSE:PPLPHARMA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.61 Max: 0.83
Current: 0.61

During the past 4 years, the highest Debt-to-Equity Ratio of Piramal Pharma was 0.83. The lowest was 0.04. And the median was 0.61.

NSE:PPLPHARMA's Debt-to-Equity is ranked worse than
72.71% of 817 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs NSE:PPLPHARMA: 0.61

Piramal Pharma Debt-to-Equity Historical Data

The historical data trend for Piramal Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Debt-to-Equity Chart

Piramal Pharma Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

0.04

0.62

0.83

0.60

Piramal Pharma Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial										N/A	0.60	N/A	0.61	N/A

Competitive Comparison of Piramal Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Piramal Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Piramal Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Piramal Pharma's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(21084.2	+	26017.4)	/	79113.7
	=	0.60

Piramal Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Piramal Pharma (NSE:PPLPHARMA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Piramal Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » Debt-to-Equity

Traded in Other Exchanges

543635:India

Address

Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070

Website

https://www.piramalpharma.com

Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.

Piramal Pharma Headlines

No Headlines